Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,419 Shares of Company Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,419 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $409.77, for a total transaction of $1,401,003.63. Following the sale, the insider directly owned 101,323 shares in the company, valued at $41,519,125.71. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, October 28th, Solomon Moshkevich sold 1,162 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $495,407.08.
• On Tuesday, October 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $410,060.00.
• On Thursday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $414.22, for a total transaction of $1,242,660.00.
• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $320.73, for a total value of $962,190.00.

Natera Stock Up 0.6%

Shares of NASDAQ:NTRA opened at $391.03 on Thursday. The firm has a market cap of $56.36 billion, a P/E ratio of -287.52 and a beta of 1.55. Natera, Inc. has a 12-month low of $181.00 and a 12-month high of $437.41. The business has a fifty day simple moving average of $380.30 and a 200 day simple moving average of $268.64.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same period in the previous year, the business earned ($0.74) EPS. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. As a group, equities research analysts expect that Natera, Inc. will post -1.14 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Natera during the second quarter worth approximately $2,962,770,000. K.J. Harrison & Partners Inc bought a new stake in Natera in the second quarter worth approximately $5,117,000. Abbot Financial Management Inc. bought a new stake in Natera in the second quarter worth approximately $1,537,000. Eagle Health Investments LP acquired a new position in Natera in the second quarter valued at approximately $4,302,000. Finally, BlueCrest Capital Management Ltd acquired a new position in Natera in the second quarter valued at approximately $11,695,000. 99.90% of the stock is owned by institutional investors.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Medicare coverage for Signatera in HCC could improve patient access and support adoption of Natera’s cancer-monitoring tests. The coverage milestone adds to the commercial opportunity for its oncology business. Natera Medicare coverage for Signatera in HCC
• Positive Sentiment: New ESMO oncology evidence was described as broadening the case for Natera’s cancer-testing portfolio, potentially reinforcing the longer-term growth story. ESMO data broaden Natera’s oncology case
• Neutral Sentiment: Natera was expected to report earnings on November 5, making results and management’s outlook a near-term catalyst; the preview article did not provide reported results. Natera earnings preview
• Neutral Sentiment: The reported analyst consensus price target was $394.31, close to the share price cited in the provided market background, suggesting limited implied upside from that target alone. Natera consensus target price
• Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The scheduled nature and relatively small size of the sale may temper its significance as a signal about management’s outlook. CFO share sale report

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent analyst reports. Stephens lifted their price objective on Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Rothschild & Co Redburn initiated coverage on shares of Natera in a research report on Tuesday, September 8th. They set a “buy” rating and a $385.00 target price for the company. Piper Sandler raised their price target on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Royal Bank Of Canada boosted their price target on shares of Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Natera from $360.00 to $460.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $394.31.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.